Physician profile
David Liff
NPI 1699951921
$6,090.79
in general payments reported to CMS, 2019-2025
36 companies · $2,817 in 2025
The $2,817 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $191 · 2021: $436 · 2022: $659 · 2023: $873 · 2024: $632 · 2025: $2,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,322.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,117.86 | 2019-2025 | |
| Boston Scientific Corporation | $608.93 | 2022-2025 | Watchman Access System, Bodyguardian, Watchman |
| Pfizer INC. | $473.35 | 2019-2025 | |
| Medtronic, INC. | $463.31 | 2025 | Symplicity G3, Ffrangio |
| E.R. Squibb & Sons, L.L.C. | $423.27 | 2019-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $333.80 | 2022-2025 | Ffrct |
| Astrazeneca Pharmaceuticals Lp | $332.04 | 2019-2025 | Farxiga, Wainua |
| Novo Nordisk INC | $262.48 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $210.18 | 2020-2024 | Xarelto |
| Amgen INC. | $189.56 | 2019-2025 | Repatha, Repatha |
| Inari Medical, INC. | $161.33 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sanofi-Aventis U.S. LLC | $157.73 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $149.44 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $143.72 | 2025 | |
| Philips North America LLC | $137.61 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.13 | 2021-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $116.35 | 2021-2025 | Opsumit, Opsynvi, Uptravi |
| Merck Sharp & Dohme LLC | $115.84 | 2021-2025 | Verquvo, Capvaxive |
| United Therapeutics Corporation | $79.10 | 2025 | Tyvaso |
| Cvrx, INC. | $62.68 | 2025 | Barostim Neo System |
| Esperion Therapeutics, INC. | $55.59 | 2021-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $55.24 | 2022-2023 | Amvuttra |
| Vital Connect, INC | $39.00 | 2025 | Vitalpatch Rtm |
| Kestra Medical Technology Services, INC. | $36.18 | 2025 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $29.75 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $26.90 | 2024 | Arcalyst |
| Lilly USA, LLC | $26.17 | 2025 | Mounjaro |
| Atricure, INC. | $25.60 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Abbott Laboratories | $21.99 | 2025 | Amplatzer Amulet |
| Siemens Medical Solutions USA, INC. | $21.75 | 2023 | Somatom X.Cite |
| Bayer Healthcare Pharmaceuticals INC. | $18.07 | 2025 | |
| Bridgebio Pharma, INC. | $17.36 | 2025 | Attruby |
| Daiichi Sankyo INC. | $15.58 | 2023 | Injectafer |
| Astellas Pharma US INC | $15.37 | 2019 | |
| Scpharmaceuticals INC. | $14.36 | 2025 | |
| Gilead Sciences, INC. | $14.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Liff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.